Adjuvant activity of polar glycopeptidolipids of Mycobacterium chelonae (pGPL-Mc) on the immunogenic and protective effects of an inactivated influenza vaccine.
Mice injected intraperitoneally with 2.5 or 25 mg/kg of pGPL-Mc, before, during or after the administration of a monovalent inactivated influenza vaccine (8 IU of A/New Jersey/X53), exhibited significantly very high haemagglutination inhibition (HI) antibody titers (up to 8 fold) as compared to vaccine controls. Treatment with pGPL-Mc has increased the protective effect of the vaccine by completely abolishing, in certain treatment groups, the onset of symptoms of disease and mortality after a lethal challenge with 5 LD50 of A/PR/8/34 virus, 60 days after the first vaccination. Moreover, the development of visible pulmonary lesions significantly decreased in surviving vaccinated mice treated with 25 mg/kg of pGPL-Mc on day D0. These results suggest that pGPL-Mc is a potent adjuvant to the immunogenic and protective effect of inactivated influenza vaccines.
Gjata
B
B
Institut d'Immunologie Animale et Comparée, Ecole Nationale Vétérinaire d'Alfort, Maisons-Alfort, France.
Hannoun
C
C
Boulouis
H J
HJ
Neway
T
T
Pilet
C
C
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D005260:Female; D006017:Glycolipids / Q000008:administration & dosage / Q000494:pharmacology*; D006020:Glycopeptides / Q000008:administration & dosage / Q000494:pharmacology*; D007252:Influenza Vaccines / Q000276:immunology*; D007274:Injections, Intraperitoneal; D051379:Mice; D008815:Mice, Inbred Strains; D016926:Mycobacterium chelonae / Q000737:chemistry*; D015164:Vaccines, Inactivated / Q000276:immunology
D000276:Adjuvants, Immunologic; D006017:Glycolipids; D006020:Glycopeptides; D007252:Influenza Vaccines; D015164:Vaccines, Inactivated